CJC-1295 and BPC-157 turn up in the same online stacks and the same search, but they share almost nothing except a vial size. One is an engineered version of a hormone that was taken through two dose-ranging studies and a phase 2 trial before its developer stopped; the other is a peptide whose human record is three small reports and whose dose figures were never measured against anything. This page puts the two records next to each other — what each source states, how often each figure is cited, and what the figures look like on a syringe (sources opened 2026-11-02). It reports figures; it suggests none.
The full record for each is on its own page: CJC-1295 dosage and BPC-157 dosage. Vial arithmetic for any water volume is in the CJC-1295 calculator and the BPC-157 calculator.
The two records in one table
| CJC-1295 (with DAC) | BPC-157 | |
|---|---|---|
| What it is | 29-residue GHRH analogue with an albumin-binding Drug Affinity Complex | Synthetic 15-residue peptide, "body protection compound" |
| Molecular weight (PubChem) | 3,647.2 g/mol | 1,419.5 g/mol |
| How it acts | GHRH receptor on the pituitary; raises growth hormone and IGF-1 | No receptor established in the sources read |
| Human dosing source | Two 2006 studies, 30 to 90 mcg/kg SC, single or weekly/biweekly | None; three uncontrolled reports, 30 people |
| Half-life | 5.8 to 8.1 days; about 8 days | Under 30 minutes in rats and dogs |
| ClinicalTrials.gov, 2026-11-02 | 1 study, terminated | 4 studies, 1 completed (a gummy) |
| Circulating figure (this site, 2026-09-18) | 1 to 2 mg a week | 250 to 500 mcg once or twice daily |
| US label (DailyMed, 2026-11-02) | None | None |
The row that decides how to read everything else is the dosing source. CJC-1295's figure comes from studies built to find a dose and measure what it did to growth hormone; BPC-157's comes from convention.
What the CJC-1295 studies did
Teichman and colleagues ran two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, lasting 28 and 49 days. The first gave one of four single subcutaneous doses; the second gave two or three doses weekly or every two weeks. A single injection raised mean growth hormone two- to tenfold for six days or more and IGF-1 one-and-a-half- to threefold for nine to eleven days; after repeated doses IGF-1 stayed above baseline for up to 28 days. The authors judged it relatively well tolerated, particularly at 30 or 60 mcg/kg, and reported no serious adverse reactions.
Ionescu and Frohman gave healthy men aged 20 to 40 a single 60 or 90 mcg/kg injection and sampled blood every 20 minutes overnight before and a week after. Growth hormone kept its pulses; what rose was the trough between them, 7.5-fold, lifting mean growth hormone by 46% and IGF-1 by 45%. The two doses did not differ.
The developer, ConjuChem, then registered a 12-week phase 2 trial in people with HIV-associated abdominal fat (NCT00267527, enrolment listed as 120). It is marked terminated and has no posted results. No later registration exists.
What the BPC-157 record holds
The 2026 systematic review by Poolton and colleagues, searched to 1 June 2026, found three human studies: knee injections in 16 people, bladder instillation in 12 and an intravenous safety pilot in 2. All were uncontrolled and judged poor quality. The registry adds a completed 40-person study of a 500 mcg gummy with no control arm, a recruiting hamstring-strain study and a rotator-cuff study not yet recruiting. The pharmacokinetics are known only from rats and dogs, set out on BPC-157 half-life. The daily figures in circulation trace to none of these.
Weekly against daily
The schedules attached to each compound follow from how long it lasts. CJC-1295 with DAC attaches to albumin in the blood and carries a half-life of about a week, which is why its studies gave single injections and weekly or biweekly repeats. BPC-157 disappears within minutes in animal plasma, and the figures cited for it are daily. Put on one calendar, a weekly 2 mg of CJC-1295 and a twice-daily 500 mcg of BPC-157 amount to 2 mg and 7 mg a week: the compound with the smaller per-injection figure is cited at the larger weekly total. That comparison is arithmetic on circulating figures, not a finding about either.
The no-DAC form is a separate case. It is a different molecule in practice, cleared in minutes, and is cited at 100 to 300 mcg one to three times a day on vendor pages; no human study of it was found. The DAC and no-DAC distinction is set out on CJC-1295 DAC vs no DAC.
The arithmetic per vial
Both are sold in 5 mg and 10 mg vials, and units depend only on concentration.
| Vial | Water | Concentration | mcg per U-100 unit | 250 mcg | 500 mcg | 1 mg | 2 mg |
|---|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5,000 mcg/mL | 50 | 5 units | 10 | 20 | 40 |
| 5 mg | 2 mL | 2,500 mcg/mL | 25 | 10 | 20 | 40 | 80 |
| 5 mg | 3 mL | 1,667 mcg/mL | 16.7 | 15 | 30 | 60 | 120 |
| 10 mg | 1 mL | 10,000 mcg/mL | 100 | 2.5 | 5 | 10 | 20 |
| 10 mg | 2 mL | 5,000 mcg/mL | 50 | 5 | 10 | 20 | 40 |
| 10 mg | 3 mL | 3,333 mcg/mL | 33.3 | 7.5 | 15 | 30 | 60 |
The 250 and 500 mcg columns are where BPC-157's circulating figures land, the 1 and 2 mg columns where CJC-1295's do. A 5 mg vial holds two and a half 2 mg amounts or ten 500 mcg amounts. The trial doses of CJC-1295, 2.1 to 6.3 mg at 70 kg, would need between 42% and more than a whole 5 mg vial per injection. One unit is 0.01 mL; the insulin syringe units page shows the barrels, and the water volumes for each compound are worked on CJC-1295 reconstitution and BPC-157 reconstitution.
What is not established
No study has compared the two or given them together. The CJC-1295 trials were short studies in healthy adults measuring hormone levels, not outcomes, and the one patient trial stopped without results. BPC-157 has no controlled human study at all. Medibact's CJC-1295 guide and BPC-157 guide cover the compounds. Decisions about administering anything belong with a clinician.
Sources and dates
Opened 2026-11-02: PubMed abstracts for Teichman SL et al., J Clin Endocrinol Metab 2006;91(3):799-805 (PMID 16352683) and Ionescu M, Frohman LA, J Clin Endocrinol Metab 2006;91(12):4792-7 (PMID 17018654); ClinicalTrials.gov record NCT00267527 and searches "CJC-1295" (1) and "BPC-157" (4); DailyMed SPL searches for both (0); PubChem CIDs 91971820 and 9941957. Carried with their read dates: circulating figures from this site's CJC-1295 and BPC-157 dosage pages (2026-09-18); the Poolton 2026 systematic review (2026-10-22); the BPC-157 rat and dog half-lives (this site's half-life page, 2026-10-28). Molecule-count, weekly-total and unit arithmetic by this site. Corrections go to the contact page.